PTGS2 and cancer: It changes a putative stimulatory protein (Sp1) binding site in the promoter of COX-2 between −766 and −761 bp [44], but it creates an E2 promoter factor (E2F) binding site, leading to high transcription activity and increased COX-2 expressions which might be involved in the development of cancers [45].